Statera Biopharma, Inc.
Statera Biopharma, Inc. (STAB) Revenue
Annual & quarterly revenue history · segment & region breakdown
STAB · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsStatera Biopharma, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2021.
Revenue trend
2021 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | +$0.00B | — |
| 2012-12-31 | $0.00B | -$8.79B | -100.00% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Statera Biopharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Statera Biopharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Statera Biopharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
STAB revenue · 4 questionsSTAB's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2021.
▸ Source: FMP · Statera Biopharma, Inc. SEC filings · GAAP · Statera Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026